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Abstract
Although most HIV-1 infections worldwide result from heterosexual transmission, most vaccine candidates have focused on induction
of systemic immunity and protection. We hypothesized that combining systemic priming with mucosal boosting would induce mucosal
immunity that would protect from intravaginal challenge. Macaques were primed systemically with recombinant vaccinia viruses and
boosted mucosally using inactivated SHIV89.6 plus adjuvant. Other animals received protein boosts with adjuvant alone. Priming and
boosting induced antiviral IgG and IgA antibodies. Such antibodies were induced to a lesser degree in animals receiving boosts alone.
Anti-SHIV T cell responses were induced only in the prime-boost animals. Immunized animals and controls were challenged intravaginally
with SHIV89.6 and significant reductions in proviral and viral RNA loads were observed in the prime-boost animals. The boost-only animals
did not have significant viral load reductions. These data suggest that cellular immunity was required for protection from intravaginal
challenge. This immunization regimen provides a promising lead for vaccine development.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Mucosal transmission of HIV-1 after heterosexual con-
tact is the primary route of infection for women throughout
the world (UNAIDS/WHO, 2000). However, the majority
of candidate vaccines have utilized methods to induce sys-
temic or gastrointestinal immune responses, and they have
been evaluated primarily for protection against intravenous
or intrarectal challenge (reviewed in Bogers et al., 2000;
Nathanson et al., 1999). Additional studies designed to test
vaccine protection against intravaginal challenge are needed
to explore the variables inherent in this important route of
HIV infection.
Simian immunodeficiency virus (SIV) infection of ma-
caques has been used extensively in simulating HIV-1 in-
fection and AIDS. However, it is impractical to evaluate
candidate vaccines against HIV envelope (Env) proteins for
use in humans in this model due to the inadequacy of
infection of and disease in macaques and chimpanzees with
HIV-1. Thus, SIV/HIV chimeric viruses (SHIV) have been
constructed, in which the rev, tat, and env genes of SIV have
been replaced with those of HIV-1 (Igarashi et al., 1994; Li
et al., 1992; Luciw et al., 1995; Reimann et al., 1996b).
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These chimeras replicate in macaques with relatively low
pathogenicity, unless serially passaged in vivo (Joag et al.,
1996; Reimann et al., 1996a; Stephens et al., 1996). Vaccine
candidates targeting HIV-1 envelope can be assessed in the
SHIV macaque model of infection.
While extensive research on the immune system of the
genital tract of female macaques during intravaginal infec-
tion with SIV have been performed (Miller, 1994), few
reports have been published showing protective effects of
vaccine candidates when the animals are challenged intra-
vaginally with SIV or SHIV (Buge et al., 1997; Israel et al.,
1999; Joag et al., 1998; Johnson et al., 1999; Marthas et al.,
1992; Marx et al., 1993; Mascola et al., 2000; Miller et al.,
1997). These mucosal immunization protocols, as well as
other HIV vaccines, can be classified into four groups; (1)
subunit or nonreplicating, such as viral proteins; (2) repli-
cating recombinant vectors, such as recombinant vaccinia
virus (rW) encoding HIV or SIV genes; (3) live-attenuated
SIV, HIV, or SHIV; and (4) combinations of these.
From these studies, as in the macaque vaccine literature
as a whole, it is not clear which immune responses correlate
with protection, especially because reports which have as-
sayed neutralizing plasma and vaginal antibodies together
with cytotoxic T lymphocytes (CTL) in the PBMC have
only recently been published. Live, attenuated lentivirus
infection has been shown to provide the best protective
efficacy against different routes of challenge (Johnson and
Desrosiers, 1998), suggesting that sustained, high-level an-
tigen production is necessary in an effective vaccine. How-
ever, the safety of such a vaccine has been questioned after
disease progression in neonatal and adult macaques vacci-
nated with highly attenuated SIV has been reported (Baba et
al., 1995, 1999). Two studies published recently have dem-
onstrated that human HIV neutralizing monoclonal antibod-
ies of the IgG subclass delivered intravenously can protect
against oral or vaginal challenge with SHIV (Baba et al.,
2000; Mascola et al., 2000). Thus as with intravenous in-
fection, very high titers of neutralizing antibodies can block
infection. However, if HIV vaccines fail to achieve and
sustain such high titers, additional cellular and humoral
immunity at the mucosal surface would be beneficial.
Prime-boost vaccines, where the priming and boosting
components consist of different modalities, are found to be
particularly effective in inducing protective immunity. Ef-
forts have focused on replicating vectors that could produce
viral antigens inside host cells and allow epitopes to be
presented in MHC class I for CTL recognition. Combining
vector priming (rVV) with subunit antigen boosts (gp120 or
gp160) was found to enhance protection from i.v. challenge
above subunit vaccination alone (Hu et al., 1992). However,
prime-boost regimens using rVV or recombinant adenovirus
with subunit boosts intramuscularly or orally and intratra-
cheally have not been successful in protection from intra-
vaginal challenge (Buge et al., 1997; Israel et al., 1999).
Cholera toxin (CT) and heat-labile enterotoxin (LT) have
been extensively explored as mucosal adjuvants in murine
models of infection (reviewed in Freytag and Clements,
1999; Snider, 1995). However, these proteins are highly
toxic and are not recommended for human immunizations.
An LT mutant, LT(R192G), has a mutation at one amino
acid, eliminating the trypsin cleavage site required for bio-
logical activation and thus greatly reducing its toxicity
(Dickinson and Clements, 1995). This compound has the
ability to induce mucosal and systemic antibodies and CTL
against a variety of pathogens in mice (Belyakov et al.,
2000; Cardenas-Freytag et al., 1999; Choi et al., 2002;
Chong et al., 1998; Lee et al., 1999; Morris et al., 2000;
O’Neal et al., 1998) and macaques (Belyakov et al., 2001)
when administered with antigens.
Thus, we wanted to utilize LT(R192G) as an adjuvant in
a prime-boost vaccination of Macaca nemestrina, which we
hypothesize will provide potent mucosal immunity against
intravaginal challenge with SHIV89.6. In this article, we
describe a novel immunization protocol of systemic priming
with rVV expressing HIV-1 Env and SIV Gag-Pol along
with mucosal boosting intragastrically (i.g.) and intranasally
(i.n.) of LT(R192G) plus aldrithiol-2 (AT-2)-inactivated
SHIV89.6. This inactivation procedure appears to retain the
functional conformation of envelope of lentiviruses (Rossio
et al., 1998).
Results
Immunization procedure
Three groups of animals were immunized: primed and
boosted (Group 1, n  5), boosted only (Group 2, n  3);
and controls (control group, n  3; Table 1). Priming was
done systemically using replicating rVV expressing HIV-
189.6 Env (vT107) and SIVmac251 Gag-Pol (vAbT394) at
weeks 0 and 4. Sham priming was performed with wildtype
vaccinia virus (NYCBH) at weeks 0 and 4. Boosting was
performed i.g. and i.n. at weeks 12 and 19 with AT-2-
inactivated SHIV89.6 and LT(R192G) and i.n. only at week
36. Control animals received boosts of the LT mutant only
at the same time points via the same routes.
SHIV challenge
After completion of the immunization regimen, all 11
animals were inoculated intravaginally with 200 50% tissue
culture infectious doses (TCID50) SHIV89.6 at week 40, 4
weeks after the third booster. One animal in the control
group (F91286) did not become infected after challenge
(Table 1, Figs. 3 and 4) and was rechallenged 14 weeks
later. Four weeks prior to all challenges and the rechallenge,
the animals were treated with medroxyprogesterone, which
has been shown to decrease the thickness of the vaginal
epithelium and increase the rate of infection (Marx et al.,
1996; Sodora et al., 1998). In exploratory studies, 200
TCID50 of the same viral stock was found to infect 2/2 M.
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nemestrina inoculated intravaginally, whereas 0/2 animals
that received 20 TCID50 became infected (data not shown).
SHIV-specific antibodies in plasma
Plasma antibodies against SHIV were analyzed by
ELISA (Tables 2 and 3). Anti-SHIV IgG was first detected
at 1 week after the first mucosal boost (Table 2). All five
Group 1 animals and one of the animals in Group 2 had
detectable IgG antibodies against SHIV (1:50–1:1250) by
week 21, 2 weeks after the second mucosal booster. At 3
weeks postchallenge, an antibody response could be de-
tected only in the plasma of those five immunized animals
that had detectable antibody levels prior to challenge, sug-
gesting an anamnestic response (Table 2). At 3 weeks
postinfection (w.p.i.) all but one of the remaining Group 1
animals and the Group 2 responder had increases in their
IgG titers (1:1250–8800). None of the control animals had
detectable IgG levels at this time point. All of the Group 1
animals had anti-SHIV IgG titers of 1:3900–7000 at 6 w.p.i.
These titers were significantly higher than those of the
Group 2 and control animals (P  0.02 and P  0.001,
respectively). In addition, the two seronegative animals in
Group 2 seroconverted by 6 weeks postchallenge but their
responses were lower (1:250-1:3200) than those seen in the
animals that were both primed and boosted. None of the
three control animals had detectable anti-SHIV antibody
responses at this time point. At 8 w.p.i. two of the controls
developed antibodies to SHIV (1:250), whereas the remain-
ing animal in the control group (F91286) did not serocon-
vert and was subsequently discovered to be uninfected by
other parameters (Table 1). ELISA results were confirmed
Table 1
Immunization components and coculture results
Animal Primesa Boostsb Coculture results (w.p.i.)c
0 1 2 3 4 5 6 7 8 10 12
A98045 vT107vAbT394 LT(R192G)SHIV           
93169d vT107vAbT394 LT(R192G)SHIV   
J91354 vT107vAbT394 LT(R192G)SHIV           
98063 vT107vAbT394 LT(R192G)SHIV           
A98068 vT107vAbT394 LT(R192G)SHIV           
F93006 NYCBH LT(R192G)SHIV           
J92468 NYCBH LT(R192G)SHIV           
M92077 NYCBH LT(R192G)SHIV           
J93076 NYCBH LT(R192G)           
98129 NYCBH LT(R192G)           
F91286e NYCBH LT(R192G)           
a Priming was done at weeks 0 and 4 by skin scarification.
b Boosting was done i.g. and i.n. at weeks 12 and 19 and i.n. at week 36.
c All animals were challenged with 200 TCID60 SHIV89.6 intravaginally.
d Animal 93169 died during anesthesia for a routine blood draw at 2 weeks postchallenge.
e Animal F91286 was rechallenged 14 weeks after initial challenge, results reflect cocultures after second challenge.
Table 2
Anti-SHIV plasma IgG antibody titers
Animal Immunizationc Titers (week)a,b
0 3 5 6 13 14 16 21 40 43 46 48
A98045 Primeboost 50 50 50 ND 50 ND 50 100 300 1250 5000 4700
93169d Primeboost 50 50 50 ND 50 ND 100 100 300 ND ND ND
J91354 Primeboost 50 50 50 ND 250 ND 1250 1250 300 250 6500 5800
98063 Primeboost 50 50 ND 50 50 ND 50 50 100 4100 3900 4400
A98068 Primeboost 50 50 ND 50 50 ND 50 250 100 8800 7000 7500
F93006 Boost only 50 50 ND 50 ND 50 50 100 100 5800 3200 4200
J92468 Boost only 50 50 ND 50 ND 50 50 50 50 50 1250 250
M92077 Boost only 50 50 ND 50 50 ND 50 50 50 50 250 1250
J93076 Control 50 50 ND 50 ND 50 50 50 50 50 50 250
98129 Control 50 50 ND 50 ND 50 50 50 50 50 50 250
F91286 Control 50 50 ND 50 50 ND 50 50 50 50 50 50
a Animals were challenged with SHIV89.6 at week 40.
b Numbers in bold indicate positive results.
c Animals were primed at weeks 0 and 4 and boosted at weeks 12, 19, and 36.
d Animal 93169 died during anesthesia for a routine blood draw at week 42 (2 weeks postchallenge).
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by Western blot analysis (data not shown). Anti-gp120
serum antibodies were not detected in any of the animals
after priming or boosting (data not shown).
Low levels of anti-SHIV IgA plasma antibodies were
detected by ELISA after two boosts in the primed and
boosted animals (Table 3). By the time of challenge, four of
the animals in Group 1 and two of the Group 2 animals had
detectable IgA antibodies (1:50–1:100). There was no evi-
dence for an anamnestic IgA response in the plasma during
the short follow-up period. At 3 weeks postchallenge, all
Group 1 animals and two animals in Group 2 had increased
or sustained levels of vaginal IgG anti-SHIV antibodies (not
shown). SHIV-specific IgA antibodies or neutralizing anti-
bodies were not detected in any of the vaginal washes of
these animals (data not shown). Anti-SHIV IgG and IgA
antibodies from the rectal swabs also were not detected by
ELISA assay (data not shown). Neutralizing antibodies in
the plasma before and early after challenge of all 11 animals
were not detected (data not shown).
CD4 T cell proliferation against SHIV
PBMC from the animals were stimulated with serial
dilutions of AT-2 inactivated SHIV89.6 in a proliferation
assay (Fig. 1). Responses were detected in the two Group 1
animals that were tested after priming (98063 and A98068).
After two boosts, high proliferation responses were detected
only in the PBMC of the Group 1 animals, and the responses
were higher for animals 98063 and A98068 than observed
after priming alone. The responses in the Group 1 animals
were significantly higher than those of the animals in Group 2
and the control group (P  0.01 and P  0.03, respectively).
SHIV-specific CD8 intracellular interferon- (IFN)
responses
CD8 T cell responses against Env and Gag-Pol were
determined at time points throughout the study using an
intracellular cytokine assay to measure antigen-specific
IFN production (Fig. 2). Responses against Env were not
prevalent in the PBMC of the Group 1, Group 2, or control
animals both before and after SHIV challenge (Fig. 2A).
However, Gag-Pol-specific PBMC responses were detected
in Group 1 and Group 2 animals (Fig. 2B). Responses to
these antigens were seen prior to challenge in 17/43 PBMC
samples from the Group 1 animals (40%), 7/24 PBMC
samples from the Group 2 animals (29%), and 3/26 PBMC
samples from the controls (12%). The difference in CD8 T
cell responses between Group 1 and Group 3 was significant
(P  0.003).
Between 3 and 8 weeks postchallenge, few CD8 T cell
responses were seen in any of the 11 animals for Env (Fig.
2A). However, anti-Gag-Pol responses were observed in the
PBMC of animals in all three groups (Fig. 2B).
Cervical cytobrushings sampled throughout this study
did not yield consistent, usable cell numbers for the intra-
cellular IFN assay. Therefore, cervical T cell responses
could not be evaluated.
Virus isolation and viral load
All animals were tested for circulating virus by three
methods: PBMC coculture, PCR for PBMC proviral DNA,
and plasma viral RNA by bDNA assay. The immune re-
sponses of the individual animals together with their level of
protection are presented in Table 4. All animals except one
became infected by coculture assay (Table 1). The animals
in Group 1 became negative by coculture between 6 to
10 w.p.i. Two animals in Group 2 became virus negative by
week 12 postinfection and one animal remained virus pos-
itive through 12 w.p.i. During the 12 weeks of follow up, we
could consistently isolate virus from the PBMC of the two
infected controls and one of the Group 2 animals.
The two control animals that did become infected had
high proviral loads in their PBMC through 10–15 w.p.i.
Table 3
Anti-SHIV plasma IgA antibody titers
Animal Immunizationc Titers (week)a,b
0 3 5 6 13 14 16 21 40 43
A98045 Primeboost 50 50 50 ND 50 ND 50 50 100 50
93169d Primeboost 50 50 50 ND 50 ND 50 50 50 ND
J91354 Primeboost 50 50 50 ND 50 ND 50 100 100 50
98063 Primeboost 50 50 ND 50 50 ND 50 50 50 50
A98068 Primeboost 50 50 ND 50 50 ND 50 50 100 450
F93006 Boost only 50 50 ND 50 ND 50 50 50 50 50
J92468 Boost only 50 50 ND 50 ND 50 50 50 50 50
M92077 Boost only 50 50 ND 50 50 ND 50 50 50 50
J93076 Control 50 50 ND 50 ND 50 50 50 50 50
98129 Control 50 50 ND 50 ND 50 50 50 50 50
F91286 Control 50 50 ND 50 50 ND 50 50 50 50
a Animals were challenged with SHIV89.6 at week 40.
b Numbers in bold indicate positive results.
c Animals were primed at weeks 0 and 4 and boosted at weeks 12, 19, and 36.
d Animals 93169 died during anesthesia for a routine blood draw at week 42 (2 weeks postchallenge).
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with peaks of 4.9  103 and 2.5  104 copies/g (Fig. 3C).
Other M. nemestrina (97070 and 94075) inoculated intra-
vaginally with the same dose of this SHIV89.6 stock had
peak proviral loads of 1.1–6.7  103 copies/g and re-
mained positive through 15 weeks postchallenge (Ambrose
et al., 2001).
DNA PCR revealed significant levels of provirus in the
PBMC of only one of four surviving Group 1 animals
(A98045), despite the fact that all four were productively
infected (see below). This animal had a peak proviral load
of 6.8  103 copies/g DNA (Fig. 3A) and became provi-
rus-negative at 12 weeks postinfection. Two other animals
in this group were consistently negative and one animal
(J91354) was slightly positive above the limit of detection
(100 copies/g DNA) at weeks 4 and 10 postinfection only.
One Group 2 animal (F93006) had multiple positive PCRs
for viral DNA in the PBMC with a peak of 1.3  103
copies/g and becoming negative at 12 weeks p.i., and the
other two animals were negative throughout the study (Fig.
3B). The proviral peaks of the Group 1 animals only were
significantly lower than the levels of the control animals (P
 0.05).
Viral RNA was detected in all coculture-positive animals
and varied in magnitude in each group (Fig. 4). The four
surviving Group 1 animals had viremia peaks at 3–4 weeks
postchallenge (Fig. 4A). One of these animals had a high
viremic peak (A98045, 3.1  106 copies/ml) and had un-
detectable levels by 8 w.p.i., whereas the average viral RNA
peak of the other three was 1.6  104 copies/ml and they
became negative by 4–6 weeks postchallenge. The Group 2
animals had an average viral RNA peak of 1.0  105 and
became negative between 4–8 weeks after challenge (Fig.
4B). The two infected controls had peaks of 3.5  105 and
7.2  106 copies/ml and they were still positive at 10–15
weeks postinfection (Fig. 4C). Two other unimmunized
control animals had viral RNA peaks of 1.1–8.7  105
(Ambrose et al., 2001). Plasma viral RNA peaks of the
Group 1 animals were significantly lower than those of the
control animals (P  0.05) but not of the Group 2 animals
(P  0.4). The viremia peaks of the Group 2 animals
showed trends toward significance as compared to the peaks
of the control animals (P  0.09).
Discussion
We have described a novel method of immunization,
which combines systemic priming with mucosal boosting,
using inactivated, conformationally intact SHIV virions.
This immunization regimen induced significant antiviral
systemic and mucosal immune responses in the limited
number of animals used in this study. Suppression of viral
replication in animals that were immunized using this pro-
tocol suggests partial protection mediated through these
immune responses, presumably through a reduction in early
viral replication. Alternatively, the observed partial protec-
tion could be the result of blocking of target cell infection at
the vaginal mucosa. We detected only low levels of non-
neutralizing vaginal IgG antibodies against SHIV89.6 and
consider the latter alternative therefore unlikely.
Fig. 1. PBMC proliferation responses when stimulated with AT-2-inactivated SHIV89.6 (0.1 g/ml) 1–2 weeks after the second priming (white bars) and 2
weeks after the second booster (black bars) of Group 1, Group 2, and control animals. Responses are represented as cpm; ND, not done. Five
SHIV89.6-infected animals had responses ranging 768–3370 (positive controls) and three uninfected animals had responses ranging 27–520 (negative
controls).
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Previous studies have demonstrated possible roles for
both neutralizing antibodies and components of the cellular
immune response in suppressing viral replication (Barouch
et al., 2002; Wyand et al., 1999). We did not detect any
virus-neutralizing antibodies in either plasma or mucosal
secretions of the immunized animals. This lack of induction
of neutralizing antibodies could be a function of the viral
preparations used for the mucosal immunizations: AT-2
inactivated SHIV retains the native Env glycoprotein con-
formation (Rossio et al., 1998), but recent data suggest that
some lentiviral preparations may rapidly lose gp120 from
the virion surface (Chertova et al., 2002). Although not
specifically investigated for the SHIV89.6 preparation used
here, such loss of glycoproteins could be a potential cause
for the observed lack of induction of virus-neutralizing
antibodies. The absence of neutralizing antibodies after
Fig. 2. Intracellular IFN staining of CD8CD69 PBMC in response to Env (A) and Gag-Pol (B) stimulation. Responses from all individual animals are
pooled by group: Group 1 (), Group 2 (E), and controls (‚). The percentages of antigen-specific IFN-positive cells were plotted after subtraction of
spontaneous IFN-producing cells with wild-type W stimulation. The limit of detection was 0.1% of the CD8CD69 cells (dashed line).
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challenge is puzzling; it is possible that viral challenge
primarily enhanced the preexisting immune response in-
duced by immunization. Efficient induction of antibody
responses to new epitopes may require infection with a
higher replication rate than the one we used for these studies
(Rasmussen et al., 2001).
Comparison of the two vaccination regimens demon-
strates that priming and boosting is more efficient in induc-
ing antiviral immunity than boosting alone, in accordance
with earlier studies (Hu et al., 1992). The Group 1 animals
had higher levels of antibodies than the Group 2 animals. In
addition, T cell proliferation was only observed in the
PBMC from the animals that had been primed and boosted,
but not in those of the animals that received the mucosal
booster vaccinations after sham priming. Interestingly, there
was no clear difference in the levels or frequencies of CD8
T cell responses to viral antigens between the two groups.
Other studies have suggested that the LT(R192G) adjuvant
directs the immune response toward a Th1 bias (Chong et
al., 1998), and our data, albeit limited, support that sugges-
tion.
Parameters for viral replication that were studied in our
animals after challenge include the reisolation of virus from
peripheral blood cells, the quantitation of PBMC proviral
loads by DNA PCR, and the determination of plasma viral
loads in plasma by bDNA assay. Each of these assays
suggest reduced levels of virus replication in the immunized
animals compared to the controls. The most striking reduc-
tion of viral burden is found in the fully immunized animals:
those that received both the recombinant vaccinia priming
and the protein boost with adjuvant. Conversion to a “virus
negative” status by coculture occurs relatively early in these
animals, and both quantitative assays for viral nucleic acids
show significant differences compared to the control ani-
mals. When comparing numerical values for these measure-
ments, there appears to be some reduction of viral replica-
tion as well in the animals that were not primed (Group 2),
but the numbers in this group and the control group are
small and the differences between these two groups are not
statistically significant. A finding that the mucosal immuni-
zation regimen by itself, without systemic priming, can
potentially induce protective systemic and mucosal re-
sponses is of great interest as such preparations are rela-
tively easy to administer. Although we used intragastric
immunization as a part of our regimen in this study, this
method can conceivably be replaced by oral administration
in the presence of acid-neutralizing substances to achieve
the same effect. Because parenteral immunization is not
necessary for induction of mucosal antiviral immunity, an
oral and/or intranasal HIV-1 vaccine would greatly increase
the potential acceptance in developing countries, allowing
more widespread vaccination.
If true differences in the levels of viral replication be-
tween the Group 1 and Group 2 animals exist, a more
comprehensive analysis of the immune responses between
greater numbers of animals in these groups could elucidate
which components are required for protection. The most
striking difference between the two groups is the absence of
T cell proliferation to SHIV antigens in PBMC from the
Group 2 animals. We have not analyzed mucosal sites for
helper T cell or CTL responses, and a possibility exists that
such responses were induced locally but not systemically.
Such analyses will be included in future studies.
Table 4
Summary of immune responses detected during immunization protocol and the viral outcomes postchallenge
Group Animal Plasma
IgGa
Plasma
IgAa
Vaginal
IgGb
CD4
prolif c
CD8
IFN d
Plasma
RNAe
PBMC
DNAf
Cocultureg
A98045 300 100  2.0 4.90 3.1  106 6820 
Prime-boost 93169 300 50  1.8 0.86 NA NA NA
J91354 1250 100  3.3 1.79 1.3  104 129 
98063 100 50  2.1 0.47 1.9  104 101 
A98068 250 100  1.7 3.21 1.5  104 101 
M93006 100 50  1.1 2.89 1.7  105 1340 
Boost F92468 50 50 / 0.7 1.07 3.1  104 114 
M92077 50 50  1.3 0 1.0  105 101 
J92076 50 50  0.7 0 7.2  105 25400 
Control 98129 50 50  1.1 0.28 3.5  105 4930 
F91286 50 50  0.8 0 500 101 
NA, not available; ND, not done.
a Titers of anti-SHIV IgG or IgA determined by ELISA.
b , detectable antibodies after challenge before controls became positive; , detectable antibodies before challenge; /, borderline responses
detected.
c Proliferation response against 0.1 g/ml SHIV after two boosts, expressed as stimulation indices (SI).
d Highest CD8CD69 cell response against Env or Gag-Pol, expressed as % responding CD8CD69 cells.
e Peak plasma RNA load, expressed as SIV copies/ml plasma.
f Peak PBMC DNA load, expressed as SIV copies/g DNA.
g , 1–4 positive cocultures; , 5–7 positive cocultures; , 8–10 positive cocultures.
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Materials and methods
Animal care
Eleven adult female pigtailed macaques (M. nemestrina)
which were negative for SIV, SRV-2, and STLV-1 were
used. These animals were between 4 and 7 years old and
mensing. The animals were housed at the Washington Re-
gional Primate Research Center. All macaque procedures
were carried out with the approval of the Animal Care and
Use Committee at the University of Washington. During all
procedures, the animals were anesthetized with an intramus-
cular injection of 10–15 mg ketamine-HCl/kg of body
weight.
Cell-culture medium
In vitro cultures were performed in RPMI 1640 (Gibco-
BRL, Gaithersburg, MD) containing 25 mM HEPES, 10%
fetal calf serum (FCS; Hyclone, Logan, UT), 100 U each of
penicillin and streptomycin (Sigma, St. Louis, MO), and 50
m 2-mercaptoethanol (JT Baker, Phillipsburg, NJ).
SHIV stock and inactivation
The virus used in this study was SHIV89.6 (a kind gift
from Y. Lu, Avant Immunotherapeutics, Needham, MA),
which has been described previously (Reimann et al.,
1996b). The stock used was passaged once in vivo in a
rhesus macaque and briefly cultured on rhesus macaque
PBMC. The viral concentration of the stock was determined
to be 103 TCID50/ml by culture on CEM  174 cells and
p27 production (SIV-1 p27 Antigen ELISA kit; ZeptoMe-
trix, Buffalo, NY).
Aldrithiol-2 (AT-2) inactivation was performed as pre-
viously reported with modifications (Rossio et al., 1998).
Briefly, bulk cultures of AA2 cells were infected with the
virus stock at 37°C until cytopathic effects (CPE) were
Fig. 3. Viral DNA levels in the PBMC of the Group 1 (A), Group 2 (B), and control (C) animals after intravaginal challenge with SHIV89.6. Viral DNA is
represented as SIV copies per microgram of PBMC DNA as determined by PCR. Animals 97070 and 94075 are unimmunized controls infected intravaginally
with the same challenge dose (see text).
185Z. Ambrose et al. / Virology 308 (2003) 178–190
significant (approximately 2 days). Cell supernatant was
harvested and stored at 4°C. Pelleted cells were resuspended
in fresh medium and incubated for two more days. Super-
natant was harvested and combined with the previous har-
vest. The supernatant volume was concentrated fivefold in a
tangential flow concentrator (Millipore, Bedford, MA) us-
ing a molecular weight cutoff of 100 kDa. AT-2 was added
to the virus at a final concentration of 400 M and the
mixture was incubated for 1 h in a 37°C water bath. Inac-
tivated virus was pelleted through 20% glycerol in PBS at
19K for 1.5 h at 4°C. The pellet was gently resuspended in
PBS and layered over a cold 30%/45% sucrose step gradient
and centrifuged at 45K for 1.5 h at 4°C. The virus was
collected from the interface and mixed 2.1 with PBS and
overlaid on 20% glycerol/PBS at 45K for 1 h at 4°C. The
virus pellet was gently resuspended in PBS and frozen at
70°C in 1 ml aliquots. Total protein concentration was de-
termined to be 850 l/ml (BCA assay; Pierce, Rockford, IL).
Inactivation was verified by culturing 10 g of the AT-2
inactivated virus on 2  107 AA2 cells for 2 weeks. No
cytopathic effects were observed.
Immunization
Animals were inoculated by dermal scarification on the
back at weeks 0 and 4: five animals received 1  108
PFU vT107 (HIV-189.6 Env) and 1  108 PFU vAbT394
(SIVmac251 Gag-Pol) and six animals received 2  108 PFU
NYCBH (wild-type; Table 1). At weeks 12 and 19, eight
animals received (1) an i.n. inoculation in one nostril of 85
g AT-2 inactivated SHIV89.6 and 50 g LT(R192G) and
(2) 85 g AT-2-inactivated SHIV89.6 and 50 g
LT(R192G), following 25 ml 0.2 M sodium bicarbonate via
an intragastric feeding tube placed through the other nostril
into the stomach. Three animals received the same mucosal
boosts with the omission of AT-2 inactivated SHIV89.6,
which was replaced with the same volume of RP-10. At
week 36, i.n. inoculations were repeated in all 11 animals.
SHIV challenge
Four weeks prior to and 1 week following challenge,
each animal was given 30 mg medroxyprogestrone acetate
Fig. 4. Viral RNA levels in the plasma of the Group 1 (A), Group 2 (B), and control (C) animals after intravaginal challenge with SHIV89.6. Viral RNA is
represented as SIV copies per milliliter of plasma as determined by bDNA assay. Animals 97070 and 94075 are unimmunized controls infected
intravaginally with the same challenge dose (see text).
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i.m. (Depo-Provera; Pharmacia & Upjohn, Kalamazoo, MI).
Inoculation of all animals was given atraumatically through
a small tube inserted into the vagina with 200 TCID50 of
SHIV89.6 within 1 h after thawing. Animal J91286 was
rechallenged in the same manner 14 weeks after the first
challenge.
Blood and mucosal samples
Blood was taken at multiple time points throughout the
study in vacutainers containing preservative-free heparin
(immunological assays) or EDTA (virological assays).
PBMC were separated over a 95% lymphocyte separa-
tion medium (immunological assays; Organon Teknika,
Durham, NC) or 95% lymphoprep medium (virological
assays; Life Technologies, Rockville, MD) gradient and
used fresh or frozen at 80°C or in liquid nitrogen. Plasma
was also separated by centrifugation and frozen at 20°C.
Vaginal washes were obtained by instilling and removing 1
ml of sterile PBS into the vagina, which was frozen at
20°C. Vaginal washes were discarded if they contained
visible blood contamination. Rectal swabs were collected
by wiping the rectal mucosal surface with a cotton swab,
which was placed in 1 ml of sterile PBS and frozen at
20°C.
Binding and neutralizing antibodies
Maxisorp plates (Nunc, Naperville, IL) were coated
overnight with 1 g/ml (plasma ELISA) or 3 g/ml (vag-
inal wash ELISA) of AT-2 inactivated SHIV89.6 lysate or
gp120 (AIDS Reagent and Reference Program, Rockville,
MD) in carbonate buffer. Plates were washed four times
with 0.1% Triton X-100 in PBS (wash buffer) and then
blocked with 5% nonfat milk in PBS for 1 h at 37°C. Plasma
was diluted to 1:50 in 1% Triton X-100 buffer and titrated
in duplicate. Vaginal washes and rectal swabs were diluted
2:1 in 1% Triton X-100 and tested in duplicate. Samples
were incubated for 1 h at 37°C. After washing, rabbit-anti-
human IgG-HRP or rabbit-anti-human IgA-HRP (1:5000,
Dako, Carpinteria, CA) in 1% Triton X-100 was added and
incubated for 1 h at 37°C. Turbo TMB (Pierce) was added
to the plates and allowed to develop and stopped with 1 M
sulfuric acid. Plates were read at 450 nm on a THERMO-
max ELISA plate reader with SOFTmax software (Molec-
ular Devices, Sunnyvale, CA). Plasma titers were expressed
as endpoint dilutions, defined as twofold above background
of prebleeds, and vaginal washes were expressed as OD/100
l of diluted wash.
Neutralization assays were performed on plasma at 0, 40,
and 43 weeks and sterile-filtered vaginal washes at weeks
43 and 48 as described previously (Crawford et al., 1999).
The SHIV89.6 stock used in this assay was produced in
human PBMC and titered in an MT-2 killing assay. The
dilutions used for this assay were 1:20 for plasma and 1:5
for vaginal washes.
Western blot analysis
Western blots of SIV antigens were made as previously
described (Kuller et al., 1998). The blots were incubated
with plasma samples diluted 1:100 in 5% milk and 0.05%
Tween 20 in PBS for 1 h at room temperature, followed by
incubation with sheep anti-human IgG-HRP (Amersham
Pharmacia, Piscataway, NJ). The blots were then incubated
in a chemiluminescent reagent (ECL; Amersham Pharma-
cia) and visualized on X-ray film.
Proliferation assay
PBMC were plated at 1  105/well in round-bottom
96-well plates in triplicate. AT-2 inactivated SHIV89.6 was
added to each well in dilutions. Negative control wells
received medium without antigen and positive control wells
received PHA (1:100; Boehringer Mannheim, Mannheim,
Germany). After 3 days in culture at 37°C, 5% CO2, 1
Ci/well [3H]thymidine (ICN, Costa Mesa, CA) was added.
The cells were cultured for an additional 18 h and then
harvested on filters (Skatron Instruments, Sterling, VA).
Filters were removed and placed in 3 ml liquid scintillation
fluid (Packard, Meriden, CT) and counted on a -scintilla-
tion counter (Beckman, Fullerton, CA). Responses were
plotted as the change in counts per minute (cpm) of the
average of stimulated triplicate wells minus the spontaneous
cpm of the cells cultured in medium only, or cpm.
Intracellular cytokine staining
The intracellular cytokine staining assay was described
previously (Ambrose et al., 2001). In brief, monocyte target
cells from PBMC in 48-well plates were infected with WT
vaccinia (NYCBH) or rW (vT107 or vAbT394) at an m.o.i.
of 10 for 4 h. Targets were washed with PBS. Fresh autol-
ogous effector cells were added to the targets from mono-
cyte-depleted PBMC at a ratio of 1:1. The cells were incu-
bated for 12 h; the last 4 h were in the presence of GolgiPlug
(PharMingen, San Diego, CA). Effector cells were col-
lected, washed in RP-10, and stained on the surface with
antibodies against CD8 (biotin; Becton-Dickinson, Moun-
tain View, CA), streptavidin-TC (Caltag, South San Fran-
cisco, CA), and CD69 (PE; Becton Dickinson). The cells
were permeabilized with the Cytofix/Cytoperm kit (Phar-
Mingen) and stained intracellularly for IFN (FITC; Phar-
Mingen). Cells were evaluated by FACScan and CellQuest
software (Becton-Dickinson).
Responses are expressed as the percentage of CD8
CD69 cells that produce IFN after stimulation with rW
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above that of the wild-type W. Responses were not included
if the percentage of IFN-producing cells when stimulated
with WT vaccinia was above 1%. The limit of detection was
0.1% of CD8 CD69 cells.
Virus isolation and viral load assays
Infection of the animals was measured by three methods.
First, fresh PBMC (5  106) from each animal were cocul-
tured with CEM174 cells (5  108) at 37°C for 1 week.
Coculture supernatant was analyzed for viral p27 antigen
(ZeptoMetrix). After sampling, half of the culture medium
was replaced and additional CEM174 cells were added if
necessary. Sampling and medium replacement was repeated
for 6 weeks. After two consecutive positive assays, the
coculture was considered positive and discarded.
Second, quantification of SIV DNA in PBMC was de-
termined by QC-PCR as previously described (Watson et
al., 1997). Briefly, DNA samples were mixed with compet-
itor DNA of pCon-1 plasmid containing an internally de-
leted SIV gag insert. Primers used for amplification were:
5, AAAGCCTGTTGGAGAACAAAGAAG, and 3,
AATTTTACCCAGGCATTTA. The thermocycling condi-
tions used for PCR were 96°C for 11 min, followed by 41
cycles of 96°C for 15 s, 55°C for 1 min, and 72°C for 30 s,
followed by an extension at 72°C for 9 min. Amplified
products were separated on 3% agarose gels and visualized
on a Gel-Doc 2000 documentation system (Bio-Rad) to
determine band intensities. The limit of detection was 100
copies/g DNA.
Plasma SIV bDNA assays were performed at Bayer as
previously described (Dailey et al., 1995). The limit of
detection was 500 copies/ml plasma.
Statistical analysis
Statistics comparing the three groups of animals to each
other for antibodies and proliferation assays were performed
using a two-tailed unpaired t test with 95% confidence
interval (CI) using Prism software (GraphPad, San Diego,
CA). Comparisons of the CD8 T cell intracellular IFN
responses of animals in the three groups were performed
using generalized estimating equations with a log link and
exchangeable correlation structure (courtesy of B. Richard-
son, Fred Hutchinson Cancer Research Center, Seattle,
WA). Comparisons of viral DNA or RNA levels were done
using the log values in a one-sided Chi-square test with 95%
CI (log cutoffs of 3.0 and 5.0, respectively; Prism). Two
unimmunized control animals that were inoculated with the
same amount of virus were included in the viral load or
virus isolation analyses only. Undetectable immune re-
sponses or viremia were represented as the midpoint value
between 0 and the level of detection.
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